A novel function of p53: A gatekeeper of retinal detachment

American Journal of Pathology

Volumn 181, Issue 3, 2012, Pages 866-874

  Lei, Hetian ^a,b   Rheaume, Marc Andre ^b   Cui, Jing ^c   Mukai, Shizuo ^b   Maberley, David ^c   Samad, Arif ^d   Matsubara, Joanne ^c   Kazlauskas, Andrius ^a,b  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NUTLIN 3; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RABBIT; RETINA DETACHMENT; VITREORETINOPATHY;

ANIMALS; APOPTOSIS; CELL AGING; CELL PROLIFERATION; COLLAGEN; CONJUNCTIVA; FIBROBLASTS; HUMANS; IMIDAZOLES; MICE; MODELS, BIOLOGICAL; PIPERAZINES; RABBITS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RETINAL DETACHMENT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 84865222233     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.05.036     Document Type: Article

References (61)

1. D. Han Proliferative Vitreoretinopathy D.M. Albert, J.W. Miller, D.T. Azar, B.A. Blodi, 2008 Elsevier Saunders Philadelphia 2315 2324
2. S.R. Wilkes, C.M. Beard, L.T. Kurland, D.M. Robertson, W.M. O'Fallon The incidence of retinal detachment in Rochester, Minnesota, 19701978 Am J Ophthalmol 94 1982 670 673
3. M.H. Haimann, T.C. Burton, C.K. Brown Epidemiology of retinal detachment Arch Ophthalmol 100 1982 289 292
4. D.G. Charteris Growth factors in proliferative vitreoretinopathy Br J Ophthalmol 82 1998 106
5. R.G. Michels, C.P. Wilkinson, T.A. Rice Retinal Detachment 1990 Mosby St Louis 669 706
6. H. Mietz, K. Heimann Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal diseases Br J Ophthalmol 79 1995 874 877
7. P. Girard, G. Mimoun, I. Karpouzas, G. Montefiore Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery Retina 14 1994 417 424
8. A. Lle Prez, R. Campos Fernndez, F. Lpez Santovea, G. Snchez Lorente, F.J. Hernndez Martinez, C. Navarro Palop [Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery] Spanish Arch Soc Esp Oftalmol 75 2000 741 750
9. H. Nagasaki, H. Ideta, A. Uemura, H. Morita, K. Ito, J. Yonemoto Comparative study of clinical factors that predispose patients to proliferative vitreoretinopathy in aphakia Retina 11 1991 204 207
10. E. Rodriguez de la Rua, J.C. Pastor, J. Aragon, A. Mayo-Iscar, V. Martinez, J. Garcia-Arumi, A. Giraldo, M.R. Sanabria-Ruiz Colmenares, I. Miranda Interaction between surgical procedure for repairing retinal detachment and clinical risk factors for proliferative vitreoretinopathy Curr Eye Res 30 2005 147 153
11. W. Tseng, R.T. Cortez, G. Ramirez, S. Stinnett, G.J. Jaffe Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery Am J Ophthalmol 137 2004 1105 1115
12. Y. Yoshino, H. Ideta, H. Nagasaki, A. Uemura Comparative study of clinical factors predisposing patients to proliferative vitreoretinopathy Retina 9 1989 97 100
13. P. Wiedemann, R.D. Hilgers, P. Bauer, K. Heimann Daunomycin Study Group Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial Am J Ophthalmol 126 1998 550 559
14. R.H. Asaria, C.H. Kon, C. Bunce, D.G. Charteris, D. Wong, P.T. Khaw, G.W. Aylward Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial Ophthalmology 108 2001 1179 1183
15. W.M. Schiff, J.C. Hwang, M.D. Ober, J.L. Olson, E. Dhrami-Gavazi, G.R. Barile, S. Chang, N. Mandava Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy Arch Ophthalmol 125 2007 1161 1167
16. K. Oh, M. Hartnett, I.M. Landers Pathogenic Mechanisms of Retinal Detachment S. Ryan, 2006 Elsevier Mosby Philadelphia
17. P. Campochiaro The Pathogenesis of Proliferative Vitreoretinopathy S. Ryan, 2006 Elsevier Mosby Philadelphia
18. P.A. Campochiaro Mechanisms in ophthalmic disease: pathogenic mechanisms in proliferative vitreoretinopathy Arch Ophthalmol 115 1997 237 241
19. C. Baudouin, D. Fredj-Reygrobellet, W.C. Gordon, F. Baudouin, G. Peyman, P. Lapalus, P. Gastaud, N.G. Bazan Immunohistologic study of epiretinal membranes in proliferative vitreoretinopathy Am J Ophthalmol 110 1990 593 598
20. S.A. Vinores, P.A. Campochiaro, B.P. Conway Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes Invest Ophthalmol Vis Sci 31 1990 14 28
21. A. Andrews, E. Balciunaite, F.L. Leong, M. Tallquist, P. Soriano, M. Refojo, A. Kazlauskas Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy Invest Ophthalmol Vis Sci 40 1999 2683 2689
22. S.G. Robbins, R.N. Mixon, D.J. Wilson, C.E. Hart, J.E. Robertson, I. Westra, S.R. Planck, J.T. Rosenbaum Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases Invest Ophthalmol Vis Sci 35 1994 3649 3663
23. J. Cui, H. Lei, A. Samad, S. Basavanthappa, D. Maberley, J. Matsubara, A. Kazlauskas PDGF receptors are activated in human epiretinal membranes Exp Eye Res 88 2009 438 444
24. H. Lei, A. Kazlauskas Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells J Biol Chem 284 2009 6329 6336
25. H. Lei, G. Velez, P. Hovland, T. Hirose, D. Gilbertson, A. Kazlauskas Growth factors outside the PDGF family drive experimental PVR Invest Ophthalmol Vis Sci 50 2009 3394 3403
26. H. Lei, G. Velez, A. Kazlauskas Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53 Mol Cell Biol 31 2011 1788 1799
27. A.J. Levine, M. Oren The first 30 years of p53: growing ever more complex Nat Rev Cancer 9 2009 749 758
28. P. Hainaut, M. Hollstein p53 and human cancer: the first ten thousand mutations Adv Cancer Res 77 2000 81 137
29. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, E.A. Liu In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
30. C. Prives Signaling to p53: breaking the MDM2-p53 circuit Cell 95 1998 5 8
31. Y. Ofir-Rosenfeld, K. Boggs, D. Michael, M.B. Kastan, M. Oren Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26 Mol Cell 32 2008 180 189
32. M. Sasaki, K. Kawahara, M. Nishio, K. Mimori, R. Kogo, K. Hamada, B. Itoh, J. Wang, Y. Komatsu, Y.R. Yang, H. Hikasa, Y. Horie, T. Yamashita, T. Kamijo, Y. Zhang, Y. Zhu, C. Prives, T. Nakano, T.W. Mak, T. Sasaki, T. Maehama, M. Mori, A. Suzuki Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11 Nat Med 17 2011 944 951
33. P. Secchiero, R. Bosco, C. Celeghini, G. Zauli Recent advances in the therapeutic perspectives of Nutlin-3 Curr Pharm Des 17 2011 569 577
34. R.C. Brennan, S. Federico, C. Bradley, J. Zhang, J. Flores-Otero, M. Wilson, C. Stewart, F. Zhu, K. Guy, M.A. Dyer Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a Cancer Res 71 2011 4205 4213
35. H. Lei, G. Velez, J. Cui, A. Samad, D. Maberley, J. Matsubara, A. Kazlauskas N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy Am J Pathol 177 2010 132 140
36. S. Rosenkranz, K.A. DeMali, J.A. Gelderloos, C. Bazenet, A. Kazlauskas Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis J Biol Chem 274 1999 28335 28343
37. H. Lei, P. Hovland, G. Velez, A. Haran, D. Gilbertson, T. Hirose, A. Kazlauskas A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy Invest Ophthalmol Vis Sci 48 2007 2335 2342
38. S. Pennock, M.A. Rheaume, S. Mukai, A. Kazlauskas A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy Am J Pathol 179 2011 2931 2940
39. C.A. Wong, M.J. Potter, J.Z. Cui, T.S. Chang, P. Ma, A.L. Maberley, W.H. Ross, V.A. White, A. Samad, W. Jia, D. Hornan, J.A. Matsubara Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells Can J Ophthalmol 37 2002 211 220
40. Y. Ikuno, A. Kazlauskas An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor Invest Ophthalmol Vis Sci 43 2002 2406 2411
41. D.M. Fastenberg, K.R. Diddie, N. Sorgente, S.J. Ryan A comparison of different cellular inocula in an experimental model of massive periretinal proliferation Am J Ophthalmol 93 1982 559 564
42. B.P. Zhou, Y. Liao, W. Xia, Y. Zou, B. Spohn, M.C. Hung HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation Nat Cell Biol 3 2001 973 982
43. Y. Ogawara, S. Kishishita, T. Obata, Y. Isazawa, T. Suzuki, K. Tanaka, N. Masuyama, Y. Gotoh Akt enhances Mdm2-mediated ubiquitination and degradation of p53 J Biol Chem 277 2002 21843 21850
44. T.M. Gottlieb, J.F. Leal, R. Seger, Y. Taya, M. Oren Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis Oncogene 21 2002 1299 1303
45. Y. Haupt, R. Maya, A. Kazaz, M. Oren Mdm2 promotes the rapid degradation of p53 Nature 387 1997 296 299
46. B.J. Druker, M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, J.M. Ford, N.B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones, C.L. Sawyers Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
47. Y. Ikuno, F.L. Leong, A. Kazlauskas Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor Invest Ophthalmol Vis Sci 41 2000 3107 3116
48. H. Lei, M.A. Rheaume, A. Kazlauskas Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy Exp Eye Res 90 2010 376 381
49. L.E. Giono, J.J. Manfredi Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest Mol Cell Biol 27 2007 4166 4178
50. S.M. Mendrysa, M.K. McElwee, J. Michalowski, K.A. O'Leary, K.M. Young, M.E. Perry Mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation Mol Cell Biol 23 2003 462 472
51. S.M. Mendrysa, K.A. O'Leary, M.K. McElwee, J. Michalowski, R.N. Eisenman, D.A. Powell, M.E. Perry Tumor suppression and normal aging in mice with constitutively high p53 activity Genes Dev 20 2006 16 21
52. A. Loewer, E. Batchelor, G. Gaglia, G. Lahav Basal dynamics of p53 reveal transcriptionally attenuated pulses in cycling cells Cell 142 2010 89 100
53. D.M. Fastenberg, K.R. Diddie, K. Dorey, S.J. Ryan The role of cellular proliferation in an experimental model of massive periretinal proliferation Am J Ophthalmol 93 1982 565 572
54. V. Iotsova, D. Stehelin Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein Cell Growth Differ 7 1996 629 634
55. J. Qiu, G. Wang, J. Hu, Q. Peng, Y. Zheng Id1-induced inhibition of p53 facilitates endothelial cell migration and tube formation by regulating the expression of beta1-integrin Mol Cell Biochem 357 2011 125 133
56. S.A. Morales, S. Mareninov, P. Coulam, M. Wadehra, L. Goodglick, J. Braun, L.K. Gordon Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2) Invest Ophthalmol Vis Sci 50 2009 4949 4956
57. S.A. Morales, S. Mareninov, P. Prasad, M. Wadehra, J. Braun, L.K. Gordon Collagen gel contraction by ARPE-19 cells is mediated by a FAK-Src dependent pathway Exp Eye Res 85 2007 790 798
58. S.A. Morales, S. Mareninov, M. Wadehra, L. Zhang, L. Goodglick, J. Braun, L.K. Gordon FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction Invest Ophthalmol Vis Sci 50 2009 462 469
59. S.A. Morales, D. Telander, L. Notterpek, M. Wadehra, J. Braun, L.K. Gordon Rewiring integrin-mediated signaling and cellular response with the peripheral myelin protein 22 and epithelial membrane protein 2 components of the tetraspan web Invest Ophthalmol Vis Sci 52 2011 5465 5472
60. D.G. Telander, S.A. Morales, S. Mareninov, K. Forward, L.K. Gordon Epithelial membrane protein-2 (EMP2) and experimental proliferative vitreoretinopathy (PVR) Curr Eye Res 36 2011 546 552
61. A.J. Levine, J. Momand, C.A. Finlay The p53 tumour suppressor gene Nature 351 1991 453 456